Liam Manns1, Nairne Scott-Douglas1,2,3,4,5, Marcello Tonelli1,2,3,4,6, Robert Weaver1,2, Helen Tam-Tham1,6, Christy Chong1, Brenda Hemmelgarn7,2,3,4,6. 1. Interdisciplinary Chronic Disease Collaboration, Alberta, Canada;Departments of. 2. Medicine and. 3. Libin Cardiovascular Institute, and. 4. O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada; and. 5. Alberta Health Services Kidney Health Strategic Clinical Network, Alberta, Canada. 6. Community Health Sciences. 7. Interdisciplinary Chronic Disease Collaboration, Alberta, Canada;Departments of Brenda.Hemmelgarn@ahs.ca.
Abstract
BACKGROUND AND OBJECTIVES: Awareness of CKD remains low in comparison with other chronic diseases, such as diabetes, leading to low use of preventive medications and appropriate testing. The objective of this study was to evaluate the quality of care provided to people with and at risk of CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a population-based analysis of all Albertans with eGFR=15-59 ml/min per 1.73 m2 between April 1, 2011 and March 31, 2012 as well as patients with diabetes (as of March 31, 2012). We assessed multiple quality indicators in people with eGFR=15-59 ml/min per 1.73 m2, including appropriate risk stratification with albuminuria testing and preventive medication use and screened people with diabetes using urine albumin-to-creatinine ratio and serum creatinine measurements. RESULTS: Among 96,480 adults with eGFR=15-59 ml/min per 1.73 m2, we found that 17.0% of those without diabetes were appropriately risk stratified with a measure of albuminuria compared with 64.2% of those with diabetes (P<0.001). Of those with eGFR=15-59 ml/min per 1.73 m2 and moderate or severe albuminuria, 63.2% of those without diabetes received an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker compared with 82.1% in those with diabetes (P<0.001). Statin use was also significantly lower in patients with eGFR=15-59 ml/min per 1.73 m2 without diabetes (39.2%) compared with those with diabetes (64.6%; P<0.001). Among 235,649 adults with diabetes, only 41.8% received a urine albumin-to-creatinine ratio and 73.2% received a serum creatinine measurement over 1 year. CONCLUSIONS: We identified large gaps in care, especially in those with CKD but no diabetes. The largest gap was in the prescription of guideline-concordant medication in those with CKD as well as appropriate screening for albuminuria in those with diabetes. Our work illustrates the importance of measuring health system performance as the first step in a quality improvement process to improve care and outcomes in CKD.
BACKGROUND AND OBJECTIVES: Awareness of CKD remains low in comparison with other chronic diseases, such as diabetes, leading to low use of preventive medications and appropriate testing. The objective of this study was to evaluate the quality of care provided to people with and at risk of CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a population-based analysis of all Albertans with eGFR=15-59 ml/min per 1.73 m2 between April 1, 2011 and March 31, 2012 as well as patients with diabetes (as of March 31, 2012). We assessed multiple quality indicators in people with eGFR=15-59 ml/min per 1.73 m2, including appropriate risk stratification with albuminuria testing and preventive medication use and screened people with diabetes using urine albumin-to-creatinine ratio and serum creatinine measurements. RESULTS: Among 96,480 adults with eGFR=15-59 ml/min per 1.73 m2, we found that 17.0% of those without diabetes were appropriately risk stratified with a measure of albuminuria compared with 64.2% of those with diabetes (P<0.001). Of those with eGFR=15-59 ml/min per 1.73 m2 and moderate or severe albuminuria, 63.2% of those without diabetes received an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker compared with 82.1% in those with diabetes (P<0.001). Statin use was also significantly lower in patients with eGFR=15-59 ml/min per 1.73 m2 without diabetes (39.2%) compared with those with diabetes (64.6%; P<0.001). Among 235,649 adults with diabetes, only 41.8% received a urine albumin-to-creatinine ratio and 73.2% received a serum creatinine measurement over 1 year. CONCLUSIONS: We identified large gaps in care, especially in those with CKD but no diabetes. The largest gap was in the prescription of guideline-concordant medication in those with CKD as well as appropriate screening for albuminuria in those with diabetes. Our work illustrates the importance of measuring health system performance as the first step in a quality improvement process to improve care and outcomes in CKD.
Authors: Marcello Tonelli; Paul Muntner; Anita Lloyd; Braden J Manns; Scott Klarenbach; Neesh Pannu; Matthew T James; Brenda R Hemmelgarn Journal: Lancet Date: 2012-06-19 Impact factor: 79.321
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: G F A Assogba; C Couchoud; C Roudier; C Pornet; S Fosse; I Romon; C Druet; B Stengel; A Fagot-Campagna Journal: Diabetes Metab Date: 2012-10-01 Impact factor: 6.041
Authors: Andrew J Palmer; William J Valentine; Roland Chen; Nazanin Mehin; Sylvie Gabriel; Bruno Bregman; Roger A Rodby Journal: Nephrol Dial Transplant Date: 2008-04 Impact factor: 5.992
Authors: Markus P Schneider; Silvia Hübner; Stephanie I Titze; Matthias Schmid; Jennifer Nadal; Georg Schlieper; Martin Busch; Seema Baid-Agrawal; Vera Krane; Christoph Wanner; Florian Kronenberg; Kai-Uwe Eckardt Journal: Kidney Int Date: 2015-09-02 Impact factor: 10.612
Authors: Hude Quan; Nadia Khan; Brenda R Hemmelgarn; Karen Tu; Guanmin Chen; Norm Campbell; Michael D Hill; William A Ghali; Finlay A McAlister Journal: Hypertension Date: 2009-10-26 Impact factor: 10.190
Authors: Paul Arora; Priya Vasa; Darren Brenner; Karl Iglar; Phil McFarlane; Howard Morrison; Alaa Badawi Journal: CMAJ Date: 2013-05-06 Impact factor: 8.262
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Louisa Sukkar; Amy Kang; Carinna Hockham; Tamara Young; Min Jun; Celine Foote; Roberto Pecoits-Filho; Brendon Neuen; Kris Rogers; Carol Pollock; Alan Cass; David Sullivan; Germaine Wong; John Knight; David Peiris; Martin Gallagher; Meg Jardine Journal: Diabetes Care Date: 2020-03-11 Impact factor: 19.112
Authors: Oskar Swartling; Yuanhang Yang; Catherine M Clase; Edouard L Fu; Manfred Hecking; Sebastian Hödlmoser; Ylva Trolle-Lagerros; Marie Evans; Juan J Carrero Journal: J Am Soc Nephrol Date: 2022-07-29 Impact factor: 14.978
Authors: Delphine S Tuot; Charles E McCulloch; Alexandra Velasquez; Dean Schillinger; Chi-Yuan Hsu; Margaret Handley; Neil R Powe Journal: Am J Kidney Dis Date: 2018-04-23 Impact factor: 8.860
Authors: Meghan J Elliott; Joanna E M Sale; Zahra Goodarzi; Linda Wilhelm; Andreas Laupacis; Brenda R Hemmelgarn; Sharon E Straus Journal: Health Expect Date: 2018-08-15 Impact factor: 3.377
Authors: Michelle D Smekal; Helen Tam-Tham; Juli Finlay; Maoliosa Donald; Chandra Thomas; Robert G Weaver; Robert R Quinn; Kin Tam; Braden J Manns; Marcello Tonelli; Aminu Bello; Navdeep Tangri; Brenda R Hemmelgarn Journal: BMC Nephrol Date: 2019-03-29 Impact factor: 2.388
Authors: Brenda R Hemmelgarn; Michelle D Smekal; Robert G Weaver; Chandra Thomas; Eleanor Benterud; Kin Tam; Braden J Manns; Marcello Tonelli; Juli Finlay; Maoliosa Donald; Helen Tam-Tham; Aminu Bello; Navdeep Tangri; Robert R Quinn Journal: Can J Kidney Health Dis Date: 2018-01-17
Authors: Michelle D Smekal; Helen Tam-Tham; Juli Finlay; Maoliosa Donald; Eleanor Benterud; Chandra Thomas; Robert R Quinn; Kin Tam; Braden J Manns; Marcello Tonelli; Aminu Bello; Navdeep Tangri; Brenda R Hemmelgarn Journal: Can J Kidney Health Dis Date: 2018-03-23